Armata Pharmaceuticals ARMP 深 沪
已收盘 04-02 16:00:00 美东时间
10.18
-0.380
-3.60%
华盛通- 最 高10.73
- 今 开10.56
- 成交量 2.29万股
- 最 低 10.18
- 昨 收 10.56
- 总市值 3.73亿
- 52周最高 16.34
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 0.97
- 委 比 0.00%
- 总股本 3663.28万
- 历史最高 16.34
- 量 比 0.75
- 振 幅 5.21%
- 历史最低 0.8311
- 每 手 1
- 风险率 2.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.
03-27 20:10
Armata Pharmaceuticals Q4 EPS $(3.43) Misses $(0.28) Estimate, Sales $1.085M Beat $750.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(3.43) per share which missed the analyst consensus estimate of $(0.28) by 1125 percent. This is a 1391.3 percent decrease over losses of $(0.23) per share
03-26 04:29
3 things to look forward to on Monday
U.S. stocks closed lower on Friday and ended lower for a fourth consecutive week as oil sustained higher prices despite efforts to minimize the impact of the war on the commodity sector. The benchmark...
03-21 04:57
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
Armata Pharmaceuticals ( ($ARMP) ) just unveiled an update. On March 19, 2026, ...
03-19 19:27
Armata Pharmaceuticals To Delay Announcement Of Q4, FY25 Financial Results; Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment
03-19 19:06
Armata Pharmaceuticals delays Q4 and full-year 2025 results release to March 31, 2026
Armata Pharmaceuticals delays Q4 and full-year 2025 results release to March 31, 2026 Armata said it will delay reporting its fourth-quarter and full-year results for the year ended Dec. 31, 2025, and expects to file its annual report on or before March 31, 2026. The FDA granted AP-SA02 Qualified In
03-19 19:06
Armata Pharmaceuticals delays Q4 and full-year 2025 results announcement
Armata Pharmaceuticals delays Q4 and full-year 2025 results announcement Armata said it is delaying the announcement of its financial results for the fourth quarter and the year ended Dec. 31, 2025. The company said it needs additional time to complete its financial reporting. Armata expects to file
03-19 19:02
Small-Cap healthcare stocks ranked by quant ratings after earnings season
As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factor...
03-13 21:55
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Raises Price Target to $15
HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) with a Buy and raises the price target from $9 to $15.
02-23 23:59
